Skip to content

PHVS

Pharvaris N.V.

NASDAQ · NLHealthcareBiotechnology
$33.55-3.98%

Price as of Jul 20, 2026

PHVS growth

Pharvaris N.V. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
EBITDA
-11.2%
EBIT
EPS
-0.7%
Free cash flow
-9.8%
Operating cash flow
-10.3%

Forward estimates

Revenue
EBITDA
EPS
+0.6%

Three-year CAGR

Revenue
EBITDA
-19.0%
EBIT
-16.6%
Net income
-30.9%
EPS
-19.8%
Free cash flow
-13.7%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.